



DiagnosTear Ltd. – Approval to register first patent to its TeaRx™ technology

Tel Aviv (July 22, 2019) – BioLight is pleased to announce that its subsidiary, DiagnosTear Ltd. ("**DiagnosTear**")¹, that is engaged in research, development and commercialization of a product that is based on DiagnosTear's TeaRx™ technology, which is used to diagnose, personalize treatment and monitor dry eye syndrome by examining the composition of the tear film ("**Diagnostear Product**" and the "**TeaRx™ technology**"), announced today that it received its first approval to register a patent from the European Patent Office (the "**Patent**").

The Patent, which constitutes part of family of patent registration applications submitted in Europe and in other markets, mainly in the United States, protects the algorithm at the core of the Diagnostear Product and is based on the TeaRx Technology™ owned by Diagnostear.

The Patent strengthens and thickens the IP protection of the Diagnostear Product, the TeaRx Technology™ and the competitive position of Diagnostear.

The expected expiration date of the Patent, after registering, is May 2, 2036. The Patent is subject to payment of registration fee and other technical terms, as customary.

¹ Holding via XL Vision Sciences Ltd. (wholly owned subsidiary) approx. 89% of the issued and share capital of Diagnostear (approx. 86% fully diluted).